{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:19:53Z","timestamp":1785464393620,"version":"3.56.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T00:00:00Z","timestamp":1647043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32CA009501"],"award-info":[{"award-number":["T32CA009501"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Total neoadjuvant therapy (TNT) improves tumor response in locally advanced rectal cancer (LARC) patients compared to neoadjuvant chemoradiotherapy alone. The effect of TNT on patient survival has not been fully investigated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>This was a retrospective case series of patients with LARC at a comprehensive cancer center. Three hundred and eleven patients received chemoradiotherapy (chemoRT) as the sole neoadjuvant treatment and planned adjuvant chemotherapy, and 313 received TNT (induction fluorouracil and oxaliplatin-based chemotherapy followed by chemoradiotherapy in the neoadjuvant setting). These patients then underwent total mesorectal excision or were entered in a watch-and-wait protocol. The proportion of patients with complete response (CR) after neoadjuvant therapy (defined as pathological CR or clinical CR sustained for 2 years) was compared by the \u03c72 test. Disease-free survival (DFS), local recurrence-free survival, distant metastasis-free survival, and overall survival were assessed by Kaplan-Meier analysis and log-rank test. Cox regression models were used to further evaluate DFS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The rate of CR was 20% for chemoRT and 27% for TNT (P=.05). DFS, local recurrence-free survival, metastasis-free survival, and overall survival were no different. Disease-free survival was not associated with the type of neoadjuvant treatment (hazard ratio [HR] 1.3; 95% confidence interval [CI] 0.93-1.80; P = .12).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Although TNT does not prolong survival than neoadjuvant chemoradiotherapy plus intended postoperative chemotherapy, the higher response rate associated with TNT may create opportunities to preserve the rectum in more patients with LARC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyac025","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T20:13:47Z","timestamp":1643141627000},"page":"380-388","source":"Crossref","is-referenced-by-count":20,"title":["Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4373-1431","authenticated-orcid":false,"given":"Jin K","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Marco","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Campbell S D","family":"Roxburgh","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Tung","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5054-8192","authenticated-orcid":false,"given":"Andrea","family":"Cercek","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Strombom","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa K F","family":"Temple","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett M","family":"Nash","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose G","family":"Guillem","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip B","family":"Paty","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7233-5454","authenticated-orcid":false,"given":"Rona","family":"Yaeger","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsofia K","family":"Stadler","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithat","family":"Gonen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil H","family":"Segal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane L","family":"Reidy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Varghese","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4351-2511","authenticated-orcid":false,"given":"Jinru","family":"Shia","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efsevia","family":"Vakiani","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham J","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B","family":"Romesser","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H","family":"Crane","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J","family":"Gollub","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Saltz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2538-5456","authenticated-orcid":false,"given":"J Joshua","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R","family":"Weiser","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Patil","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Garcia-Aguilar","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,12]]},"reference":[{"issue":"8843","key":"2022050615374970100_CIT0001","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0140-6736(93)90207-W","article-title":"Mesorectal excision for rectal cancer.","volume":"341","author":"MacFarlane","year":"1993","journal-title":"Lancet"},{"issue":"17","key":"2022050615374970100_CIT0002","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer.","volume":"351","author":"Sauer","year":"2004","journal-title":"N Engl J Med."},{"issue":"16","key":"2022050615374970100_CIT0003","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","article-title":"Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years.","volume":"30","author":"Sauer","year":"2012","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022050615374970100_CIT0004","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1200\/JCO.2008.19.5362","article-title":"Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.","volume":"27","author":"Sargent","year":"2009","journal-title":"J Clin Oncol."},{"issue":"4","key":"2022050615374970100_CIT0005","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/DCR.0000000000001558","article-title":"Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.","volume":"63","author":"Voss","year":"2020","journal-title":"Dis Colon Rectum."},{"issue":"1","key":"2022050615374970100_CIT0006","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/cncr.30261","article-title":"Poor compliance with adjuvant chemotherapy use associated with poorer survival in patients with rectal cancer: An NCDB analysis.","volume":"123","author":"Xu","year":"2017","journal-title":"Cancer"},{"issue":"3","key":"2022050615374970100_CIT0007","first-page":"CD004078","article-title":"Postoperative adjuvant chemotherapy in rectal cancer operated for cure.","author":"Petersen","year":"2012","journal-title":"Cochrane Database Syst Rev."},{"issue":"6","key":"2022050615374970100_CIT0008","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1016\/S1470-2045(17)30346-7","article-title":"Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer.","volume":"18","author":"Carvalho","year":"2017","journal-title":"Lancet Oncol."},{"issue":"2","key":"2022050615374970100_CIT0009","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(14)71199-4","article-title":"Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data.","volume":"16","author":"Breugom","year":"2015","journal-title":"Lancet Oncol."},{"issue":"11","key":"2022050615374970100_CIT0010","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa060829","article-title":"Chemotherapy with preoperative radiotherapy in rectal cancer.","volume":"355","author":"Bosset","year":"2006","journal-title":"N Engl J Med."},{"issue":"2","key":"2022050615374970100_CIT0011","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.radonc.2014.10.006","article-title":"No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT).","volume":"113","author":"Sainato","year":"2014","journal-title":"Radiother Oncol."},{"issue":"7","key":"2022050615374970100_CIT0012","doi-asserted-by":"crossref","first-page":"874","DOI":"10.6004\/jnccn.2018.0061","article-title":"Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology.","volume":"16","author":"Benson","year":"2018","journal-title":"J Natl Compr Canc Netw."},{"issue":"suppl_4","key":"2022050615374970100_CIT0013","doi-asserted-by":"crossref","first-page":"iv22","DOI":"10.1093\/annonc\/mdx224","article-title":"Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"28","author":"Glynne-Jones","year":"2017","journal-title":"Ann Oncol."},{"issue":"8","key":"2022050615374970100_CIT0014","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(15)00004-2","article-title":"Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.","volume":"16","author":"Garcia-Aguilar","year":"2015","journal-title":"Lancet Oncol."},{"issue":"10","key":"2022050615374970100_CIT0015","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1097\/DCR.0000000000001207","article-title":"Consolidation mFOLFOX6 chemotherapy after Chemoradiotherapy improves survival in patients with locally advanced rectal cancer: final results of a multicenter phase II trial.","volume":"61","author":"Marco","year":"2018","journal-title":"Dis Colon Rectum."},{"issue":"6","key":"2022050615374970100_CIT0016","doi-asserted-by":"crossref","first-page":"e180071","DOI":"10.1001\/jamaoncol.2018.0071","article-title":"Adoption of total neoadjuvant therapy for locally advanced rectal cancer.","volume":"4","author":"Cercek","year":"2018","journal-title":"JAMA Oncol"},{"issue":"9","key":"2022050615374970100_CIT0017","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/cncr.30600","article-title":"Total neoadjuvant therapy for rectal cancer: An emerging option.","volume":"123","author":"Ludmir","year":"2017","journal-title":"Cancer"},{"issue":"3","key":"2022050615374970100_CIT0018","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/SLA.0000000000003471","article-title":"Total Neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes.","volume":"271","author":"Petrelli","year":"2020","journal-title":"Ann Surg."},{"issue":"4","key":"2022050615374970100_CIT0019","doi-asserted-by":"crossref","first-page":"e185896","DOI":"10.1001\/jamaoncol.2018.5896","article-title":"Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after Neoadjuvant therapy.","volume":"5","author":"Smith","year":"2019","journal-title":"JAMA Oncol"},{"issue":"4","key":"2022050615374970100_CIT0020","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.sla.0000141194.27992.32","article-title":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.","volume":"240","author":"Habr-Gama","year":"2004","journal-title":"Ann Surg."},{"key":"2022050615374970100_CIT0021","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1186\/s12885-015-1632-z","article-title":"Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.","volume":"15","author":"Smith","year":"2015","journal-title":"BMC Cancer"},{"issue":"1","key":"2022050615374970100_CIT0022","doi-asserted-by":"crossref","first-page":"91","DOI":"10.21037\/jgo.2019.10.03","article-title":"Is my life going to change?-a review of quality of life after rectal resection.","volume":"11","author":"Fern\u00e1ndez-Mart\u00ednez","year":"2020","journal-title":"J Gastrointest Oncol"},{"key":"2022050615374970100_CIT0023","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.eclinm.2019.09.009","article-title":"Comparing outcomes following total neoadjuvant therapy and following neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer.","volume":"16","author":"Zhu","year":"2019","journal-title":"EClinicalMedicine"},{"issue":"10","key":"2022050615374970100_CIT0024","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju248","article-title":"Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment.","volume":"106","author":"Trakarnsanga","year":"2014","journal-title":"J Natl Cancer Inst."},{"issue":"10","key":"2022050615374970100_CIT0025","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.5858\/133.10.1539","article-title":"Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum.","volume":"133","author":"Washington","year":"2009","journal-title":"Arch Pathol Lab Med."},{"issue":"12","key":"2022050615374970100_CIT0026","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/DCR.0b013e3181f42b89","article-title":"Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization.","volume":"53","author":"Habr-Gama","year":"2010","journal-title":"Dis Colon Rectum."},{"issue":"35","key":"2022050615374970100_CIT0027","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1200\/JCO.2011.37.7176","article-title":"Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.","volume":"29","author":"Maas","year":"2011","journal-title":"J Clin Oncol."},{"issue":"9","key":"2022050615374970100_CIT0028","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S1470-2045(10)70172-8","article-title":"Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data.","volume":"11","author":"Maas","year":"2010","journal-title":"Lancet Oncol."},{"issue":"8","key":"2022050615374970100_CIT0029","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/annonc\/mdv223","article-title":"Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial\u2020.","volume":"26","author":"Fernandez-Martos","year":"2015","journal-title":"Ann Oncol."},{"issue":"2","key":"2022050615374970100_CIT0030","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00066-013-0469-0","article-title":"Preoperative chemoradiation with or without induction oxaliplatin plus 5-fluorouracil in locally advanced rectal cancer. Long-term outcome analysis.","volume":"190","author":"Calvo","year":"2014","journal-title":"Strahlenther Onkol."},{"issue":"10","key":"2022050615374970100_CIT0031","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1093\/annonc\/mds056","article-title":"Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer.","volume":"23","author":"Schou","year":"2012","journal-title":"Ann Oncol."},{"issue":"3","key":"2022050615374970100_CIT0032","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(09)70381-X","article-title":"Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.","volume":"11","author":"Chua","year":"2010","journal-title":"Lancet Oncol."},{"issue":"7","key":"2022050615374970100_CIT0033","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.7314\/APJCP.2015.16.7.2993","article-title":"Can Induction Chemotherapy before Concurrent Chemoradiation Impact Circumferential Resection Margin Positivity and Survival in Low Rectal Cancers?.","volume":"16","author":"Bhatti","year":"2015","journal-title":"Asian Pac J Cancer Prev."},{"issue":"2","key":"2022050615374970100_CIT0034","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.clcc.2016.07.020","article-title":"Capecitabine and Oxaliplatin before, during, and after radiotherapy for high-risk rectal cancer.","volume":"16","author":"Larsen","year":"2017","journal-title":"Clin Colorectal Cancer."},{"issue":"3","key":"2022050615374970100_CIT0035","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/COC.0000000000000149","article-title":"Complete neoadjuvant treatment for rectal cancer: the brown university oncology group CONTRE study.","volume":"40","author":"Perez","year":"2017","journal-title":"Am J Clin Oncol."},{"issue":"6","key":"2022050615374970100_CIT0036","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/annonc\/mdr473","article-title":"Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study.","volume":"23","author":"Mar\u00e9chal","year":"2012","journal-title":"Ann Oncol."},{"issue":"1","key":"2022050615374970100_CIT0037","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.","volume":"22","author":"Bahadoer","journal-title":"Lancet Oncol."},{"issue":"5","key":"2022050615374970100_CIT0038","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"issue":"24","key":"2022050615374970100_CIT0039","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1200\/JCO.2005.02.113","article-title":"Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921.","volume":"23","author":"Bosset","year":"2005","journal-title":"J Clin Oncol."},{"issue":"28","key":"2022050615374970100_CIT0040","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1200\/JCO.2006.06.7629","article-title":"Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.","volume":"24","author":"G\u00e9rard","year":"2006","journal-title":"J Clin Oncol."},{"issue":"8","key":"2022050615374970100_CIT0041","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S1470-2045(15)00159-X","article-title":"Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO\/ARO\/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.","volume":"16","author":"R\u00f6del","year":"2015","journal-title":"Lancet Oncol."},{"issue":"13","key":"2022050615374970100_CIT0042","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of adjuvant chemotherapy for stage III colon cancer.","volume":"378","author":"Grothey","year":"2018","journal-title":"N Engl J Med."},{"key":"2022050615374970100_CIT0043","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1200\/JCO.2020.38.15_suppl.4008","article-title":"Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial.","volume":"38","author":"Garcia-Aguilar","year":"2020","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022050615374970100_CIT0044","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.2013.51.7904","article-title":"Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial","volume":"32","author":"Schrag","year":"2014","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022050615374970100_CIT0045","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.clcc.2016.02.003","article-title":"PROSPECT Eligibility and Clinical Outcomes: Results From the Pan-Canadian Rectal Cancer Consortium.","volume":"15","author":"Boss\u00e9","year":"2016","journal-title":"Clin Colorectal Cancer."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/5\/380\/43590644\/oyac025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/5\/380\/43590644\/oyac025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T15:39:16Z","timestamp":1651851556000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/5\/380\/6547696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,12]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3,12]]},"published-print":{"date-parts":[[2022,5,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac025","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2022,3,12]]}}}